Resveratrol-derived stilbenoids and biological activity evaluation of seed extracts of<i>Cenchrus echinatus</i>L.

Silva, Adriano Antonio; Haraguchi, Shirani Kaori; Cellet, Thelma S.P.; Schuquel, Ivânia T.A.; Sarragiotto, María Helena; Vidotti, Gentil J.; Melo, Juliana Oliveira de; Bersani-Amado, Ciomar Aparecida; Zanoli, Karine; Nakamura, Celso Vataru

doi:10.1080/14786419.2011.561538

Cited by 7 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its total synthesis has been reported, albeit bearing an academic interest rather than providing a commercial perspective since it consists of a 13-step synthetic route. As for its pharmacological properties, it has shown anticancer activity by inhibiting DNA topoisomerase II (with a higher potency than etoposide) while exhibiting antiproliferative activity against adenocarcinoma cells [ 61 , 62 , 63 ]. Both cis-Miyabenol C and trans-Miyabenol C are resveratrol trimers.…”

Section: Discussionmentioning

confidence: 99%

In Silico Identification and Evaluation of Natural Products as Potential Tumor Necrosis Factor Function Inhibitors Using Advanced Enalos Asclepios KNIME Nodes

Papadopoulou

Drakopoulos

Lagarias

et al. 2021

IJMS

View full text Add to dashboard Cite

Tumor necrosis factor (TNF) is a regulator of several chronic inflammatory diseases, such as rheumatoid arthritis. Although anti-TNF biologics have been used in clinic, they render several drawbacks, such as patients’ progressive immunodeficiency and loss of response, high cost, and intravenous administration. In order to find new potential anti-TNF small molecule inhibitors, we employed an in silico approach, aiming to find natural products, analogs of Ampelopsin H, a compound that blocks the formation of TNF active trimer. Two out of nine commercially available compounds tested, Nepalensinol B and Miyabenol A, efficiently reduced TNF-induced cytotoxicity in L929 cells and production of chemokines in mice joints’ synovial fibroblasts, while Nepalensinol B also abolished TNF-TNFR1 binding in non-toxic concentrations. The binding mode of the compounds was further investigated by molecular dynamics and free energy calculation studies, using and advancing the Enalos Asclepios pipeline. Conclusively, we propose that Nepalensinol B, characterized by the lowest free energy of binding and by a higher number of hydrogen bonds with TNF, qualifies as a potential lead compound for TNF inhibitors’ drug development. Finally, the upgraded Enalos Asclepios pipeline can be used for improved identification of new therapeutics against TNF-mediated chronic inflammatory diseases, providing state-of-the-art insight on their binding mode.

show abstract

Section: Discussionmentioning

confidence: 99%